A randomized comparison of comprehensive weight loss intervention vs. usual care on recurrences of atrial fibrillation in obese patients after catheter ablation: HOBIT-AF trial
- Journal
- Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (Q1)
- Published
- 4 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Kristýna Koščálová, Peter Novodvorský, Iva Jakubíková, Adam Ševčík, Adam Rafaj, Iveta Pleyerová, et al.
- PMID
- 42980655
- DOI
- 10.1093/europace/euag178
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (top studies of the week, 15 November 2026): Weight loss improved metabolic profile, no reduction in AF recurrence
Abstract
AIMS: Obesity is one of the strongest risk factors for the development of atrial fibrillation (AF), and its reduction is associated with the alleviation of AF burden. The HOBIT-AF study aimed to evaluate the impact of complex weight loss interventions on AF recurrence rate in obese individuals after catheter ablation (CA). METHODS AND RESULTS: The HOBIT-AF was a randomized controlled trial with a 15-month treatment period (3-18 months post CA) involving complex weight-reducing interventions in the active arm. The primary outcome was the change in AF/atrial tachycardia (AT) burden assessed from baseline and the final 14-day Holter monitoring. A total of 167 individuals (aged 59 years, body mass index of 35.6 kg/m2) were randomized into the active (n = 85) and control group (n = 82). At the end of the treatment period, a mean reduction of 6.8 ± 7.0% of the initial body weight accompanied by improvement of metabolic parameters was achieved in the active group. The AF/AT burden change was 0.6 ± 2.5% (95% CI: -4.2-5.5%) in the active group and -0.9 ± 1.8% (95% CI: -4.5-3.0%) in the control group. The AF/AT recurrence-free survival during the 3-18-month follow-up period was comparable between groups (70.4% vs. 69.6%). CONCLUSION: HOBIT-AF trial showed that despite the beneficial effect of body weight reduction on metabolic profile of obese patients with predominantly paroxysmal AF after CA, no reduction in AF/AT recurrence was observed in comparison with control patients. This may be likely due to low AF burden after previous CA, limiting further improvement.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.